Pyrocalm Control Gastro-Resistant Tablets 20mg, 14 Tablets, Pack of 1

Product Information

Muscle tension caused by the body’s response to stress and anxiety may affect the muscles around the stomach, increasing pressure on the stomach which in turn pushes up acid. Since omeprazole is metabolised by CYP2C19 and CYP3A4, active substances known to inhibit CYP2C19 or CYP3A4 (such as clarithromycin and voriconazole) may lead to increased omeprazole serum levels by decreasing omeprazole's rate of metabolism. Concomitant voriconazole treatment resulted in more than doubling of the omeprazole exposure. As high doses of omeprazole have been well-tolerated adjustment of the omeprazole dose is not generally required. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated. Pyrocalm Control 20mg Gastro-Resistant Tablets contain the active substance omeprazole, which belongs to a group of medicines known as ‘proton pump inhibitors’. The treatment works by suppressing the activity of proton pumps, the proteins that produce acids in the stomach. This decreases the amount of acid in the stomach, relieving the symptoms of acid reflux and heartburn. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.

Omeprazole is safe for use in adults and children over the age of 1 year. What is Omeprazole used for? There are also several medications that interfere with digestion or the oesophagus in a way that might increase your risk of GORD. Talk to your GP about whether your medication might be causing your acid reflux, and if other treatments are available. It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms. Monitoring phenytoin plasma concentration is recommended during the first two weeks after initiating omeprazole treatment and, if a phenytoin dose adjustment is made, monitoring and a further dose adjustment should occur upon ending omeprazole treatment. You experience severe or persistent diarrhoea, as omeprazole has been associated with a small increase in infectious diarrhoea.

Serious side effects

Co-administration of atazanavir with proton pump inhibitors is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g virus load) is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; omeprazole 20 mg should not be exceeded. Ketoconazole, itraconazole, posaconazole or voriconazole (used to treat infections caused by a fungus) The inhibition of acid secretion is related to the area under the plasma concentration-time curve (AUC) of omeprazole and not to the actual plasma concentration at a given time. Concomitant administration of omeprazole with saquinavir/ritonavir resulted in increased plasma levels up to approximately 70% for saquinavir associated with good tolerability in HIV-infected patients.

Omeprazole tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine. The plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with omeprazole. The majority of patients achieve complete relief of heartburn within 7 days. Once complete relief of symptoms has occurred, treatment should be discontinued. Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely. Alopecia, photosensitivity, acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS)You get stomach pain or signs of indigestion (such as nausea, fullness, bloating especially after food intake). As in all long-term treatments, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance. Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, omeprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment. Omeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the intracellular canaliculi within the parietal cell, where it inhibits the enzyme H + K +-ATPase - the acid pump. This effect on the final step of the gastric acid formation process is dose-dependent and provides for highly effective inhibition of both basal acid secretion and stimulated acid secretion, irrespective of stimulus. Sometimes, the oesophageal sphincter weakens under excess pressure, causing stomach acid to travel up into the oesophagus. This is acid reflux. Acid reflux typically leads to heartburn, which is the name for the painful sensation of acid irritating or burning the tissues of the oesophagus. It actually has nothing to do with the heart — it gets its name because the pain is felt at the base of the chest. How do Pyrocalm Control 20mg Gastro-Resistant Tablets work?